Skip to content

IMProving Treatment of moderate to severe AtopiC Dermatitis in adults by immune- supportive Diet. A proof-of-concept study

IMProving Treatment of moderate to severe AtopiC Dermatitis in adults by immune- supportive Diet. A proof-of-concept study - IMPACDD study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56216
Enrollment
30
Registered
2023-10-13
Start date
2024-05-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatits, eczema eczema

Interventions

Patients will receive written and oral dietary advice by an allergy-specialist dietitian regarding the maintenance of a healthy and individually tailored immune-supportive diet during 4 months (incl

Sponsors

OLVG
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Age 18 years or older - Diagnosed with moderate to severe AD by the dermatologist, EASI score  7.1-72 - Able to speak and write Dutch

Exclusion criteria

Exclusion criteria: - Other skin diseases - Not able to speak or write Dutch fluently - Pregnancy - Multiple clinical relevant IgE mediated food allergies (> 1 staple food or  food group, such as cow*s milk or nuts/peanuts/seeds) - Avoidance of all dairy or gluten - Extensive eliminations due to Pollen Food Syndrome, so that a daily variety  of raw fruits and/or vegetables is not feasible - Individual patients will not start the dietary intervention just before the time of the year in which the AD is usually worsening - Antibiotics shorter than 6 weeks prior to the study - Using systemic immune suppressants or biologicals - Not willing to stop probiotic and nutrient supplements from 4 and 2 weeks  subsequently prior to the start of the study (except medically prescribed or recommended for age such as vitamin D).

Design outcomes

Primary

MeasureTime frame
Main study outcomes (no primary outcome): Differences in AD severity (including itch), cytokine production, quality of life, nutrition intake and use of medication.

Secondary

MeasureTime frame
n.a.

Countries

Netherlands

Contacts

Public ContactB.J. Vlieg-Boerstra

OLVG

b.vlieg-boerstra@olvg.nl+31205993528

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026